Patents by Inventor Linda Fredriksson
Linda Fredriksson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10676527Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: February 12, 2018Date of Patent: June 9, 2020Assignees: Ludwig Institute for Cancer Research Ltd., The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20180222984Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: February 12, 2018Publication date: August 9, 2018Applicants: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 9926372Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: October 6, 2016Date of Patent: March 27, 2018Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20170152318Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: October 6, 2016Publication date: June 1, 2017Applicants: The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 9487579Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: May 20, 2014Date of Patent: November 8, 2016Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF MARYLAND, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20140255397Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicants: Ludwig Institute for Cancer Research, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 8765671Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: February 28, 2012Date of Patent: July 1, 2014Assignees: Ludwig Institute for Cancer Research, University of Maryland, The Regents of the University of MichiganInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20120156187Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH, THE REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Patent number: 8147828Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: April 17, 2007Date of Patent: April 3, 2012Assignees: Ludwig Institute for Cancer Research, University of Maryland, The Regents of the University of MichiganInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20100221254Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.Type: ApplicationFiled: January 6, 2010Publication date: September 2, 2010Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Linda Fredriksson, Hong Li, Christina Fieber, Xuri Li, Ulf Eriksson
-
Publication number: 20090047284Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.Type: ApplicationFiled: November 19, 2007Publication date: February 19, 2009Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Linda Fredriksson, Hong Li, Christina Fieber, Xuri Li, Ulf Eriksson
-
Publication number: 20070265203Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: April 17, 2007Publication date: November 15, 2007Applicant: Ludwig Institute for Cancer ResearchInventors: Ulf Eriksson, Daniel Lawrence, Enming Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20060104978Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.Type: ApplicationFiled: October 25, 2004Publication date: May 18, 2006Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Linda Fredriksson, Hong Li, Christina Fieber, Xuri Li
-
Publication number: 20030082670Abstract: PDGF-C, a new member of the PDGF/VEGF family of growth factors, is described, as well as nucleotide sequences, its method of production, antibodies and antagonists. Also disclosed are transfected and transformed host cells expressing same and pharmaceutical compositions, and uses thereof in medical and diagnostic applications. Proteolytic processing of PDGF-C is accomplished by a serine protease. Methods for inhibiting PDGF-C activities and for treating disease caused by PDGF-C over-activity of over-expression are also disclosed.Type: ApplicationFiled: April 25, 2002Publication date: May 1, 2003Inventors: Ulf Eriksson, Linda Fredriksson